This report on G-protein coupled receptors (GPCRs) market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies engaged in manufacturing and commercialization of GPCR assays, cell lines, and consumables and entrants that are planning to invest in the GPCRs market. This report comprises an elaborate executive summary, which includes a market snapshot providing overall information of various segments and sub-segments included in the study scope. This section also provides overall information and data analysis of the global GPCRs market with respect to the leading market segments based on types of products, applications and geographic regions.

The global GPCRs market has been segmented based on of assay type, therapeutic area, and geography. Based on assay type, the GPCRs market has been categorized into six major segments: cAMP assays, calcium level detection assays, GTPγS binding assays, reporter gene assays, receptor internalization assays, and cGMP assays. The market for these segments has been extensively analyzed based on of their effectiveness, usefulness, sales, and geographic presence. Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year.

In terms of therapeutic areas, the market has been segmented into seven categories: cardiovascular system, central nervous system (CNS), respiratory system, immune system, reproductive system, oncology, and others (abdominal, urinary, orthopedics, etc.). Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year.

The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that have strong impact on the GPCRs market currently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. Porter's Five Forces analysis is also explained in this section to understand the GPCRs market considering different parameters that have an impact on the sustainability of the companies operating in the GPCRs market. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market.

Geographically, the GPCRs market has been categorized into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). Major geographic regions have been further divided into major national markets, viz. North America (the U.S. and Canada), Europe (Germany, the U.K., France, and Rest of Europe), and Asia Pacific (China, Japan, India, and Rest of Asia Pacific). Moreover, Rest of the World has been further subdivided into three regions: Latin America, the Middle East, and Africa. Market revenue in terms of USD million for the period between 2012 and 2022 along with the CAGR % from 2014 to 2022 are provided for all the regional and national markets considering 2013 as the base year.

The recommendations section included in the report would assist existing market players in expanding their market shares and new companies in establishing their presence in the global market. The report also profiles major players in the GPCRs market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include Thermo Fisher Scientific, Inc., EMD (Merck) Millipore, Becton, Dickinson and Company, PerkinElmer, Inc., Cisbio Bioassays, Enzo Life Sciences, Inc., DiscoveRx Corporation, Sigma-Aldrich Corporation, QIAGEN N.V., Promega Corporation, Abcam plc, and HD Biosciences Co. Ltd.